Moloney Securities Asset Management LLC acquired a new stake in AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 90,400 shares of the company's stock, valued at approximately $265,000.
A number of other hedge funds also recently made changes to their positions in ABCL. Arcadia Investment Management Corp MI acquired a new stake in AbCellera Biologics during the 3rd quarter worth approximately $26,000. NBC Securities Inc. lifted its holdings in AbCellera Biologics by 56.0% during the 3rd quarter. NBC Securities Inc. now owns 11,420 shares of the company's stock worth $29,000 after purchasing an additional 4,100 shares during the last quarter. Ballentine Partners LLC acquired a new stake in AbCellera Biologics during the 3rd quarter worth approximately $54,000. Clarkston Capital Partners LLC acquired a new stake in AbCellera Biologics during the 3rd quarter worth approximately $57,000. Finally, B. Riley Wealth Advisors Inc. lifted its holdings in AbCellera Biologics by 58.1% during the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 34,000 shares of the company's stock worth $88,000 after purchasing an additional 12,500 shares during the last quarter. 61.42% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Several analysts recently weighed in on ABCL shares. Benchmark reissued a "hold" rating on shares of AbCellera Biologics in a report on Tuesday, November 5th. Stifel Nicolaus reissued a "buy" rating and set a $12.00 price target (down from $14.00) on shares of AbCellera Biologics in a report on Tuesday, November 5th. Finally, KeyCorp dropped their price target on AbCellera Biologics from $5.00 to $4.00 and set an "overweight" rating for the company in a report on Wednesday, January 8th.
Check Out Our Latest Research Report on AbCellera Biologics
AbCellera Biologics Trading Up 4.1 %
NASDAQ ABCL traded up $0.13 during midday trading on Friday, hitting $3.27. The company had a trading volume of 5,957,272 shares, compared to its average volume of 3,871,791. The company has a market capitalization of $965.86 million, a PE ratio of -5.36 and a beta of 0.42. The firm has a 50-day moving average price of $3.06 and a 200-day moving average price of $2.83. AbCellera Biologics Inc. has a twelve month low of $2.34 and a twelve month high of $5.45.
AbCellera Biologics Company Profile
(
Free Report)
AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.
Further Reading
Before you consider AbCellera Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbCellera Biologics wasn't on the list.
While AbCellera Biologics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
